Biocon Limited · NSE:BIOCON
Biocon — Investor Presentation (February 2018)
29 slides from Biocon's investor presentation, February 2018
Slide 1: Biocon Limited Investor Presentation
Biocon Limited Investor Presentation February 2018 BSE: 532523 │ NSE: BIOCON │ REUTERS: BION.NS │ BLOOMBERG: BIOS IN │ WWW.BIOCON.COM
Slide 2: Safe Harbor
Safe Harbor Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements.
Slide 3: Agenda
Agenda Biocon: Who are we? Highlights • Business Highlights • Financial Highlights Business Segments • Small Molecules • Biosimilars • Branded Formulations • Novel Molecules • Research Services - Syngene Five Year Financial Summary Outlook 3
Slide 4: Who are we?
Who are we? 4
Slide 5: Biocon: Asia's Leading Biopharma Company
Biocon: Asia’s Leading Biopharma Company Our Vision To enhance global healthcare through innovative and affordable biopharmaceuticals for patients, partners and healthcare systems across the globe 5
Slide 6: The Biocon Journey: A continuous evolution
The Biocon Journey: A continuous evolution 2016 and 1978-1999 2000-2004 2005-2009 2010-2015 beyond Focused on Insulin Transforming Building the Glargine global An Enzymes into a Base Business approval and development Company Biopharma and expertise launch in and strategic company in biologics Japan
Slide 7: Evolution of Key Innovations: Making a Difference
Evolution of Key Innovations: Making a Difference 1979 - Manufacture and export of enzymes, food ingredients and brewing aids to Europe 2001 - First Indian company to be approved by US FDA for the manufacture of lovastatin from solid state fermentation 2004 - First company worldwide to commercialize
Slide 8: Recent Highlights
Recent Highlights US FDA approved Mylan/Biocon’s biosimilar Trastuzumab on December 1, 2017 Biocon and Sandoz announced an exclusive global collaboration to develop next generation biosimilar immunology and oncology products. Mylan/ Biocon’s biosimilar Insulin Glargine received positive opinion from
Slide 9: Recent Highlights - continued
Recent Highlights - continued Launched Rosuvastatin Calcium formulation in the US; partner launched the same in EU Biocon received DCGI (India) approval to conduct a Phase2/3 study in type 2 diabetes patients for our oral insulin candidate Insulin Tregopil. JDRF to support a Phase 1 study in type 1
Slide 10: Revenue Highlights
Revenue Highlights All Figures in ₹ Million except % Q3 Q3 Growth 9M 9M Growth Particulars FY17 FY18 FY17 (%) FY18 FY17 (%) - Small Molecules 3,688 4,069 (9) 10,822 12,457 (13) 16,405 - Biologics 1,898 2,224 (15) 5,294 5,385 (2) 7,018 - Branded Formulations 1,561 1,233 27 4,624 4,179 11 5,489 - Syng
Slide 11: Financial Summary
Financial Summary All Figures in ₹ Million except % Growth Growth Particulars Q3 FY18 Q3 FY17 9M FY18 9M FY17 FY17 (%) (%) Revenue 10,918 10,918 0 30,989 31,172 (1) 40,787 EBITDA 2,556 3,235 (21) 7,348 9,059 (19) 11,366 Net Profit# 919 1,713 (46) 2,420 4,846 (50) 6,199 R&D Expenses in 529 846 (37) 1
Slide 12: Business Segments
Business Segments 12
Slide 13: Growth Segments: Aligned with Shifting Paradigms
Growth Segments: Aligned with Shifting Paradigms Small Molecules – APIs and Generic Formulations Biologics – Biosimilars & Novel Biologics Branded Formulations - Formulations Business in India & UAE Research Services - Contract Research & Manufacturing 13
Slide 14: Small Molecule APIs
Small Molecule APIs Product Portfolio which leverages our core fermentation capabilities and have a high degree of complexity. Early mover in niche products at commercial scale. One of the largest producers of various fermentation based statins and immunosuppressant API in India and across the globe
Slide 15: Small Molecule Generic Formulations
Small Molecule Generic Formulations Vertically integrated business model with a nascent pipeline. Pipeline includes solid oral & parenteral products in both potent & non-potent categories of compounds. Focus therapeutic segments – Metabolics, Oncology, Immunology & Auto-immune indications. Invested
Slide 16: Biosimilars
Biosimilars Over 15 years of experience is developing biologics with four biosimilars commercialized in various markets across the globe. Strong scientific and technical capabilities with manufacturing expertise and scale to address global opportunities. Over 1500 people dedicated to support this bu
Slide 17: Biosimilars: Partnership with Mylan
Biosimilars: Partnership with Mylan BIOCON MYLAN • Global-scale, complex biologics • Strength in Regulatory/ filings manufacturing capabilities strategy • Facilities accredited by • Strong commercialization international regulatory agencies capability in US and EU. • Decade-long experience & • Marke
Slide 18: Biosimilars: Partnership with Sandoz
Biosimilars: Partnership with Sandoz Deal Structure Portfolio addresses next wave of immunology and oncology biosimilars Both companies share responsibility for end-to-end development, manufacturing and global regulatory approvals for a number of biosimilars Costs & profits are shared equally Commer
Slide 19: Disclosed Biosimilars Pipeline – a multi-billion dollar opportunity
Disclosed Biosimilars Pipeline – a multi-billion dollar opportunity Molecule Type Status Rh Insulin Regular Acting Insulin Pre-clinical (US), Marketed in EM INSULINS EU (+CHMP opinion). Under review in US, Glargine Long Acting Insulin Australia & Canada. Marketed in Japan (since Jul-16) & EMs Aspart
Slide 20: Disclosed Biosimilar Pipeline: Biocon well placed in the competitive landscape
Disclosed Biosimilar Pipeline: Biocon well placed in the competitive landscape Molecule Biosimilar Development Pipeline@ Phase I Phase 3 Regulatory Submission Approved/ Marketed EMA FDA EMA FDA pegfilgrastim DRL, Pfizer Biocon, Coherus, Biocon, Coherus, None None Sandoz, Cinfa, Apotex, Sandoz USV, A
Slide 21: Biosimilars Manufacturing: Building Global Scale
Biosimilars Manufacturing: Building Global Scale Biocon Malaysia: Asia’s largest integrated insulins manufacturing facility Biocon’s First Manufacturing expansion overseas in Iskandar, Johor. Investment of over US$275mn in the first phase. Commercial supplies initiated with OTA award by Ministry of
Slide 22: Branded Formulations
Branded Formulations A Specialty Business with regional ambitions, currently in India and UAE. Strategy focused around biologics and differentiated products as anchor brands. The UAE business sells Branded generics and in-licensed Branded products. India business organized into 5 divisions aro
Slide 23: Novel Molecules - Pipeline & Therapeutic Area Focus
Novel Molecules - Pipeline & Therapeutic Area Focus India Phase II/III Insulin Tregopil * DIABETES in T2D First-in-Class Oral, Prandial Insulin commenced Itolizumab* IND Ready Novel, humanized CD6 Antibody BVX-20# IND Ready INFLAMMATION Novel, humanized CD20 Antibody QPI-1007$ Phase III in SiRNA for
Slide 24: Novel Molecules – Progressing to key milestones
Novel Molecules – Progressing to key milestones Asset Details Tregopil USP: Oral, Ultra Rapid-Acting Phase II/III Ongoing Post- prandial glycemic control; Liver specific- portal delivery, Weight neutral Safety & tolerability established in Phase 1 studies in US – DDI, Food Effect, PK/PD Data avail
Slide 25: Syngene (Research Services Business)
Syngene (Research Services Business) Global High Growth CRO Company Established in 1994, as India’s first Contract Research Organization – 23 years of unparalleled experience in novel molecule discovery and development services One of the leading India-based contract research organizations (CRO) Int
Slide 26: Appendix
Appendix 26
Slide 27: Business Holdings Structure
Business Holdings Structure Syngene, India (73.54%)* Biocon FZ LLC (100%)/ NeoBiocon, UAE (49%) Research Services Biocon Limited, India Biocon Biologics, UK Biocon SA, Biocon Healthcare (100%) Switzerland (100%) Sdn Bhd (100%) Biocon Sdn Bhd, Biocon Biologics Biocon Pharma, Malaysia (100%) India (10
Slide 28: Five Year Financial Performance Summary (FY13-17)
Five Year Financial Performance Summary (FY13-17)# All Figures in ₹ Million except EPS Business Segment FY13 FY14 FY15 FY16 FY17$ Biopharmaceuticals 18,705 21,382 22,367 23,908 26,259 - Biopharma 15,231 17,468 18,071 19,534 20,764 - Branded Formulations 3,474 3,914 4,296 4,374 5,495 Contract Researc
Slide 29: For further information, please visit www.biocon.com
For further information, please visit www.biocon.com Investor Relations contact: Saurabh Paliwal Tel : +91 80 6775 2040 Email: investor.relations@biocon.com 29